Why the study?
AHA guidelines define Class I indications for ICD therapy in patients with various cardiac conditions, but recommendations for patients not included or well represented in clinical trials are needed.
Provides a summary of AHA Class I indications for ICD therapy across various high-risk patient populations.
Class I ICD indications guide therapy in arrest, sustained VT, and syncope; Level 3 evidence leaves need for updated trials open.
American Heart Association (AHA) guidelines recommend that Class I indications for therapy with an implantable cardioverter defibrillator (ICD) are 1) cardiac arrest due to ventricular fibrillation (VF) or ventricular tachycardia (VT) not due to a transient or a reversible cause; 2) spontaneous sustained VT; 3) syncope of undetermined origin with clinically relevant, hemodynamically significant sustained VT or VF induced at electrophysiologic study when drug therapy is ineffective, not tolerated, or not preferred; ; 4) patients with prior myocardial infarction (MI) at least 40 days previously with a left ventricular ejection fraction (LVEF) less than 35 % who are in New York Heart Association (NYHA) class II or III; 5) patients with nonischemic dilated cardiomyopathy with a LVEF less than or equal to 35 % who are in NYHA class II or III; 6) patients with prior MI at least 40 days previously with a LVEF less than 30 % who are in NYHA class I; and 7) patients with nonsustained VT due to prior MI with a LVEF
No takes yet. Share an insight, caveat, or question.
Wilbert S. Aronow (2014) conducted a review in Ventricular arrhythmias and heart failure. Implantable Cardioverter-Defibrillator (ICD) was evaluated. Implantable cardioverter-defibrillator therapy is recommended as a Class I indication by the AHA for patients with cardiac arrest, sustained VT, or specific heart failure criteria.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: